Jeff Landau

Jeff Landau's Title

Jeff Landau serves as the Senior Vice President (SVP), Head of Strategy, and Chief Business Officer. In these roles, he leverages his extensive experience in the biopharmaceutical industry to guide corporate development, strategic planning, and business operations. His leadership is instrumental in driving the company's vision and ensuring alignment with long-term goals.

Jeff Landau's Experience

With over 20 years of experience in the biopharmaceutical sector, Jeff Landau has a robust background in corporate development, corporate strategy, and new product strategy and planning. He has held key positions at leading firms, including his most recent role as Senior Vice President of Corporate Development, Commercial, and New Product Strategy at Catalyst Biosciences, Inc. His career also includes significant roles at Threshold Pharmaceuticals and Onyx Pharmaceuticals, where he oversaw global product and pipeline strategy, contributing to the companies' growth and success.

Jeff Landau's Achievements

Jeff Landau has achieved significant milestones in his career, particularly during his tenure at Catalyst Biosciences, where he was a key member of the executive management team. He was responsible for critical areas such as partnering, licensing, acquisitions, corporate strategy, pipeline and new product planning, alliance, and project management. His strategic insight and leadership have been pivotal in driving business growth and innovation, positioning the companies he has worked with at the forefront of the biopharmaceutical industry.

Jeff Landau's Education and Expertise

Jeff Landau holds an M.B.A. from the prestigious Stanford Graduate School of Business, where he honed his skills in business management and strategy. He also earned his B.S. with honors in biochemistry/biotechnology from Virginia Polytechnic Institute, providing him with a solid foundation in scientific principles and research methodologies. This unique combination of advanced business acumen and scientific expertise enables him to effectively bridge the gap between scientific innovation and commercial viability in the biopharmaceutical industry.